Filing Flows › iBio (IBIO) › Q1 FY26
iBio (IBIO) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Nov 12, 2025
iBio (IBIO) reported revenue of $100K for the first quarter fiscal 2026 (Q1 FY26) and -50% from the quarter before.
iBio, Q1 FY26: revenue $100K, net loss $5.7M, operating cash flow −$5.7M. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $100K | -50% | — |
| Operating profit | −$6.0M | — | — |
| Net earnings | −$5.7M | — | — |
| Operating cash flow | −$5.7M | — | — |
What changed
Revenue was $100K in Q1 FY26, down 50% from the previous quarter.
Operating costs exceeded revenue by $6.0M, an operating margin of -5951.0%. The quarter ended with a net loss of $5.7M, wider than the previous quarter's $5.2M loss.
Operating cash flow was −$5.7M. Non-cash charges added back $108K of depreciation and amortization and $323K of share-based compensation. Working capital and other items used $376K. Capital expenditures of $32K exceeded it, leaving free cash flow of −$5.7M.
Questions
What was iBio's revenue in the first quarter fiscal 2026?
iBio (IBIO) reported revenue of $100K for the first quarter fiscal 2026 (Q1 FY26) and -50% from the quarter before.
Source: iBio 10-Q on SEC EDGAR.